A clinical‑stage biotechnology company focused on developing therapies that target neuronal nicotinic receptors, a pathway studied for neurological and psychiatric disorders. Its drug candidates have historically been aimed at conditions such as depression, Alzheimer’s disease, and cognitive impairm...
No congressional trades have been disclosed for Targacept Inc (TRGT) yet. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
No congressional trades found for this stock.